• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Forum >Tumor-Debulking und HIPEC bei Peritonealkarzinose
【24h】

Tumor-Debulking und HIPEC bei Peritonealkarzinose

机译：腹膜癌中的肿瘤减灭和HIPEC

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cytoreductive surgery (CRS) combined with perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated improved survival in selected patients with a variety of tumors. Despite the survival benefits this treatment has been associated with high morbidity and mortality rates and the perception of the poor perioperative outcome associated with this regimen remains. This treatment modality has been consistently associated with variable rates of perioperative mortality between 0 % and 18 % and morbidity between 30 % and 70 %. Despite its existence for more than 10 years, this treatment has received heavy criticism for the morbidity and mortality rates. This consequentially resulted in a lack of randomized trials being conducted and translates into a lack of the most reliable form of scientific evidence in clinical research, hence limiting its general acceptance. To derive the maximal benefit from this treatment, careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications.
机译：细胞减少手术（CRS）结合围手术期高温腹膜内化疗（HIPEC）已证明，所选的患有多种肿瘤的患者生存期得到改善。尽管具有生存优势，但该治疗仍与高发病率和高死亡率相关，并且仍然认为与该方案相关的围手术期效果差。这种治疗方式一直与围手术期死亡率在0％至18％之间的变化率和发病率在30％至70％之间的变化率相关。尽管该疗法已经存在了10多年，但其发病率和死亡率却受到了广泛的批评。因此，这导致缺乏进行的随机试验，并导致缺乏临床研究中最可靠形式的科学证据，从而限制了其普遍接受性。为了从这种治疗中获得最大的益处，必须提倡对患者进行仔细选择，并选择最佳的术后护理，以避免不必要的并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号